Daiichi Sankyo: Breast Neoplasms trials

The registry lists 22 Breast Neoplasms studies with Daiichi Sankyo as lead sponsor. 6 are open to participants now and 7 have results posted.

Phase 1 6Phase 2 6Phase 3 5No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingNCT07701941Phase 1/2
• T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3
• A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 2
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerRecruitingNCT05950945Phase 3
• DESTINY Breast Respond HER2-(Ultra)Low EuropeRecruitingNCT05945732
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedNCT03734029Phase 3Results posted
• DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedNCT03529110Phase 3Results posted
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedNCT03523585Phase 3Results posted
• DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) ProteinCompletedNCT03368196Phase 1Results posted
• Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerCompletedNCT03366428Phase 1Results posted
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)TerminatedNCT03248492Phase 2Results posted
• Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast CancerCompletedNCT02980341Phase 1/2Results posted
• Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6iCompletedNCT06975371
• A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast CancerCompletedNCT06686602
• Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast CancerCompletedNCT06040593
• A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast CancerCompletedNCT05769751
• EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab DeruxtecanCompletedNCT05458401
• Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast CancerCompletedNCT05149014
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1
• Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)TerminatedNCT01512199Phase 1/2
• Chemotherapy in Treating Women With Metastatic Breast CancerCompletedNCT00004046Phase 2